Table 2

Procoagulant biomarkers by chronic kidney disease status.

VariablesHealthy controlCKD 3CKD 4CKD 5pp
Platelet (109/L)237.2±47.4214.8±65.0214.0±52.8195.8±58.60.1560.284
ADPLTA (%)&64.6±4.8 67.3±8.6 70.1±8.674.7±8.2*0.0410.738
Factor V (%)113.6±26.198.4±31.9106.7±36.9103.4±33.30.5330.640
Factor VII (%)74.2±14.3 94.5±18.0* 104.2±17.9*108.4±27.2*<0.0010.050
Factor VIII (%)86.5±22.3 115.3±25.1* 130.5±27.6*139.9±33.0*<0.001<0.001
VWF:Ag (%)103.1±42.4 124.7±51.4 158.9±49.9*181.8±45.6*<0.0010.011
vWF:RCo (%)99.8±29.9 115.5±43.2 150.2±45.1*168.2±41.5*<0.0010.004
Fibrinogen (g/L)3.0±0.8 3.1±0.7 3.8±0.8* 4.5±1.1*<0.0010.006
Protein C (%)105.3±17.0 99.4±18.6 93.5±17.986.6±15.2*0.0240.736
Protein S (%)76.8±23.288.2±24.694.5±20.799.5±25.50.0760.584
AT III (%)99.5±9.3103.8±12.2103.8±11.7103.1±11.80.6580.189
D-dimer (ng/ml)257±116 425±277 505±320* 842±496*<0.0010.039
APTT (s)39.0±4.537.7±3.237.5±3.739.0±4.20.2860.187
PT (s)13.4±0.613.5±0.613.5±0.613.7±0.60.3200.192
  • ADPLTA (%): platelet aggregation records were available in 49 CKD cases (15 cases in CKD 3 stage; 21 cases in CKD 4 stage; 13 cases in CKD 5 stage) and 9 healthy controls.

  • *p<0.05 versus control group;♦p<0.05 versus CKD 5 group.

  • †p Values for the adjusted model. Data are adjusted for age, sex, history of diabetes, history of coronary heart disease, smoking status, mean arterial pressure, body mass index, haemoglobin, serum albumin, cholesterol, triglyceride and urine albumin-to-creatinine ratio.

  • APTT, activated partial thromboplastin time; AT III, antithrombin III; CKD, chronic kidney disease; LTA, light transmittance aggregometry; PT, prothrombin time; vWF:Ag, von Willebrand factor antigen; vWF:RCo, vWF ristocetin cofactor activity.